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EphrinA1-EphA-receptor signaling is protective during myocardial infarction (MI). The
EphA2-receptor (EphA2-R) potentially mediates cardiomyocyte survival. To determine
the role of the EphA2-R in acute non-reperfused myocardial injury in vivo, infarct size,
inflammatory cell density, NF-κB, p-AKT/Akt, and MMP-2 protein levels, and changes
in ephrinA1/EphA2-R gene expression profile were assessed 4 days post-MI in B6129
wild-type (WT) and EphA2-R-mutant (EphA2-R-M) mice lacking a functional EphA2-R.
Fibrosis, capillary density, morphometry of left ventricular chamber and infarct dimensions,
and cardiac function also were measured 4 weeks post-MI to determine the extent of
ventricular remodeling. EphA2-R-M infarct size and area of residual necrosis were 31.7%
and 113% greater than WT hearts, respectively. Neutrophil and macrophage infiltration
were increased by 46% and 84% in EphA2-R-M hearts compared with WT, respectively.
NF-κB protein expression was 1.9-fold greater in EphA2-R-M hearts at baseline and 56%
less NF-κB after infarction compared with WT. EphA6 gene expression was 2.5-fold higher
at baseline and increased 9.8-fold 4 days post-MI in EphA2-R-M hearts compared with WT.
EphrinA1 gene expression in EphA2-R-M hearts was unchanged at baseline and decreased
by 42% 4 days post-MI compared with WT hearts. EphA2-R-M hearts had 66.7% less
expression of total Akt protein and 59% less p-Akt protein than WT hearts post-MI.
EphA2-R-M hearts 4 weeks post-MI had increased chamber dilation and interstitial fibrosis
and decreased MMP-2 expression and capillary density compared with WT. In conclusion,
the EphA2-R is necessary to appropriately modulate the inflammatory response and
severity of early injury during acute MI, thereby influencing the progression of ischemic
cardiomyopathy.
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INTRODUCTION
Myocardial Infarction (MI) is associated with an increased risk
of congestive heart failure. After the initial infarction, structural
remodeling ensues, leading to progressive ventricular dilation and
dysfunction (Kannel, 2000; Frangogiannis et al., 2002; Jugdutt,
2012). Manipulation of cell signaling represents a new therapeutic
approach to combat the development of heart failure by reducing
the severity of the original ischemic insult (French et al., 2010;
Kung et al., 2011).
The Eph receptors (Eph-R) and their ligands, the ephrins, are
the largest family of receptor tyrosine kinases. Ephrin-Eph-R sig-
naling regulates cell differentiation, proliferation, and migration
during development (Kullander and Klein, 2002; Pasquale, 2008)
and plays a pivotal role in various cancers (Brantley et al., 2002;
McCarron et al., 2010). EphrinA1, an angiogenic protein stim-
ulated by pro-inflammatory cytokines, promotes tumorigenesis
through interaction with the EphA2-R (Pandey et al., 1995; Cheng
et al., 2002; Brantley-Sieders et al., 2004a,b, 2006; Pasquale, 2008;
Miao et al., 2009; Beauchamp and Debinski, 2011). Antagonism
of the EphA2-R with lithocholic acid blocks EphA2-R phospho-
rylation and reduces cancer cell growth (Incerti et al., 2013).
Furthermore, the absence of the EphA2-R in mice confers a
predilection for hyper-responsiveness to allergens demonstrated
by increased inflammation (Okazaki et al., 2009). Conversely,
EphA2-R in other tissues has been demonstrated to enhance
inflammation via endothelial cell priming and inflammatory
cell migration (Ivanov and Romanovsky, 2006; Coulthard et al.,
2012; Funk et al., 2012; Funk and Orr, 2013). EphA2-R expres-
sion on human monocytes and coronary artery endothelial
cells, both of which express a combination of other eph-
rinA ligands and EphA receptors, may modulate inflammatory
cell transmigration (Sakamoto et al., 2011). Also, EphA2-R is
expressed on rat vascular smooth muscle cells and contributes
to ephrinA1-mediated vessel destabilization during revascular-
ization (Deroanne et al., 2003). The tissue- and cell-specific
role of EphA2-R and its interaction with other EphA-Rs and
ephrinA ligands in myocardial injury is complex and warrants
investigation.
Recently, our lab and others have reported that ephrinA1-
EphA-R signaling can be manipulated to preserve cardiomyocyte
function after MI. We have shown that ephrinA1-Fc admin-
istration is cardioprotective during MI and possibly this, at
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least in part, is mediated through the EphA2-R (Dries et al.,
2011). Goichberg et al. has shown that ephrinA1-Fc treat-
ment during MI is cardioprotective through EphA2-R-mediated
revascularization and regeneration (Goichberg et al., 2011).
Jehle et al. demonstrated that immortalized HL-1 cardiomy-
ocytes exposed to doxazocin were protected from apoptosis
by increased EphA2-R expression and reduced phosphorylation
in response to lithocholic acid (Jehle et al., 2012). Combined
with its known pro-angiogenic and pro-inflammatory actions
in the heart, we hypothesized that MI in mice lacking a func-
tional EphA2-R worsens cardiomyocyte injury and inflammation
leading to adverse remodeling and cardiac dysfunction (O’Neal
et al., 2013). To investigate this, we examined the acute response
to non-reperfused MI 4 days post-MI and the progression of
ischemic cardiomyopathy 4 weeks post-MI in EphA2-R-mutant
(EphA2-R-M) mice.
METHODS
ANIMALS
Experimental research protocols were approved by the East
Carolina University Institutional Animal Care and Use
Committee following the guidelines of the National Institutes of
Health for the Care and Use of Laboratory Animals. B6129SF2/J
mice (stock #101045) (WT) and B6129S6-Epha2tm1Jrui/J (stock
#006028; an EphA2-deficient homozygous mutant (truncated,
non-functional protein) (Brantley-Sieders et al., 2004a,b);
EphA2-R-M) mice were purchased from Jackson Laboratories.
All mice were housed in ventilated cages and animal care was
maintained by the Department of Comparative Medicine at The
Brody School of Medicine, East Carolina University. Mice were
exposed to 12/12 hour light/dark cycle conditions and received
food and water ad-libitum.
SURGICAL PROCEDURE AND TISSUE COLLECTION
Male WT and EphA2-R-M mice (8–12 weeks) were anes-
thetized with an intraperitoneal injection of 20μl/g body weight
Avertin (20mg/ml) and mechanically ventilated. The left ante-
rior descending coronary artery was permanently occluded using
an 8–0 suture. The rib cage, muscle, and skin were then closed
with a 6–0 suture. Four days or 4 weeks after surgery, mice were
anesthetized with a lethal intraperitoneal injection of 0.1mL pen-
tobarbital (390mg/mL). At the time of sacrifice, the heart was
arrested in diastole using cold KCl (30mM), excised, rinsed in
saline, and immersed in zinc fixative or snap frozen in liquid
nitrogen. For immunohistochemical staining and morphomet-
ric measurements, whole hearts were transversely sectioned into
4 slices of equal thickness and processed in an automated tissue
processor (TP1020, Leica, Nußloch, Germany), and embedded
in paraffin (Microm EC350, Richard-Allan Scientific, Kalamazoo,
MI, USA) (Beckstead, 1994; Ismail et al., 2003). Fiveμm thick sec-
tions were mounted on Superfrost Plus glass slides for histology
or immunostaining.
MORPHOMETRY AND HISTOLOGY
Morphometric measurements were performed blindly on tissue
sections 4 days and 4 weeks post-MI. Four H&E-stained (hema-
toxylin and eosin) section images of each heart were taken at
20x magnification using a DP70 digital camera. Left ventricular
(LV) cross-sectional area was measured using Scion imaging soft-
ware (Scion Corporation, Frederick, MD, USA). LV anterior wall
and septal thickness were measured using the average of 4 mea-
surements in each of the 4 sections. The area of infarction was
measured 4 days post-MI and taken as an average of total necrotic
and granulation tissue areas. Infarct size (IS) was measured and
reported as a percentage of the left ventricle.
Myocyte cross-sectional area (MCSA) was measured in 3–8
cardiomyocytes with centrally located nuclei in each of 6 images
(600x) in the endocardium and epicardium (n = 3–5/group)
using Scion imaging software (Scion Corporation, Frederick,MD,
USA).
Interstitial fibrosis was measured using a Picrosirus Red/Fast
Green staining protocol. Briefly, samples were de-paraffinized
and rehydrated, immersed in a 0.1% picrosirius red/fast green
solution (Sigma-Aldrich, 365548, F7258, P6744) for 30 minutes,
cleared, and coverslipped (Virag et al., 2007). Tissue collagen was
determined by taking 4 images at 400× in 2 sections per heart and
using Adobe Photoshop CS4 (Adobe Systems, Mountview, CA) to
count the number of red and green pixels. The percent collagen
was calculated as the number of red pixels/red + green pixels ×
100%. The numbers were averaged for each animal and the data
presented are the average of 3–5 animals per group.
IMMUNOSTAINING
Tissue sections were deparaffinized in xylene and endoge-
nous peroxidases quenched with 3% H2O2 in methanol. Slides
were rinsed in saline and incubated with antibodies to CD45
(BD Biosciences; #550539) for leukocyte infiltration, Ly6G (BD
Biosciences, #550291) for neutrophil infiltration, or CD31 (BD
Biosciences, #553371) for capillary density. For EphA6-R staining,
anti-EphA6-R (SantaCruz #25740) was used. Slides were incu-
bated with appropriate biotinylated secondary antibodies and
then with Avidin Biotin Complex (Vector Labs PK-6100). The
reaction product was visualized with DAB (Vector, SK-4100),
counterstained with methyl green, dehydrated in xylene, and
slides were coverslipped.
qRT-PCR
Whole left ventricles of uninjured (baseline) hearts and hearts 4
days post-MI fromWT and EphA2-R-Mmice were homogenized
using Trizol for RNA isolation. Purification was performed using
the Qiagen RNeasy kit. cDNA was made for each sample
using a high capacity cDNA kit. Real-time PCR (qRT-PCR)
was performed using an Applied Biosystems thermocycler.
TaqMan primers were obtained from Applied Biosciences
(ephrinA1: Mm00438660_m1, EphA1: Mm00445804_m1,
EphA2: Mm00438726_m1, EphA3: Mm00580743_m1,
EphA4: Mm00433056_m1, EphA5: Mm00433074_m1, EphA6:
Mm00433094_m1, EphA7: Mm00833876_m1, GAPDH:
Mm99999915_g1). All samples were run in triplicate and a
reaction mixture of 10μl (100 ng RNA) was amplified using
recommended conditions. Gene expression was normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
expression. Fluorescence data were analyzed using the  Ct
method.
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WESTERN BLOTTING
Whole left ventricles of baseline hearts and hearts 4 days post-
MI from WT and EphA2-R-M mice were homogenized in a
lysis buffer containing 50mM Hepes, 10mM EDTA, 100mM
NaF, 50mM sodium pyrophosphate, 1% protease, and 1% phos-
phatase inhibitors. The Bradford Assay was used to quantify
the amount of protein. Western blotting was performed on a
4–12% gradient Bis-Tris gel (BioRad) in 1 × Mops running
buffer.
Fifty micrograms of sample was loaded per well. The
gel was run for 1 h at 155V, and transferred onto pure
nitrocellulose membranes (BioRad). Antibodies: GAPDH
(Millipore, #MAB374), p-Akt (Cell Signaling, #4060), Akt
(Cell Signaling, #4691), matrix metalloproteinase-2 (MMP-2;
R&D Systems, #AF1488), and NF-κBp65 (Santa Cruz, #sc-372)
followed by appropriate secondary antibodies. All blots were
detected with Amersham ECL Advance (GE Healthcare) and
imaged on a Typhoon Imager. Densitometry was performed
using Image J software (v1.42, NIH, Bethesda, MD) and the
intensity of each protein was normalized to GAPDH.
ECHOCARDIOGRAPHY
Echocardiography was performed on conscious uninjured and
infarcted mice at 4 weeks post-MI mice after they had been accli-
mated in 2–3 sessions within 3 days prior to data acquisition
(Yang et al., 1999). A VisualSonics Vevo 2100 diagnostic ultra-
sound, using M-mode, was used to obtain LV dimensions in
diastole and systole. End-diastolic measurements (IVSd, LVPWd,
and LVIDd) were obtained at the point of maximal LV diastolic
dimension. End-systolic dimensions (IVSs, LVPWs, and LVIDs)
were measured at the time of most anterior systolic excursion of
the LVPW associated with minimal chamber dimension. Average
measurements were calculated using the leading-edge technique
of 3- to 5-consecutive sinus beats. Ejection fraction (EF) was cal-
culated from LV dimensions above using the following formula:
(LVIDd3-LVIDs3)/LVIDd3 × 100%.
STATISTICS
ANOVA (analysis of variance) with Student-Newman Keuls mul-
tiple comparison post-hoc analysis illustrated which groups were
statistically significantly different, with significance of at least
p < 0.05.
RESULTS
BASELINE CHARACTERISTICS
WT (n = 6) mice and EphA2-R-M (n = 7) mice weighed
30.22 ± 1.0 g and 22.39 g ± 0.5, respectively (p < 0.001). The
LV area of EphA2-R-M hearts was 40% smaller than WT hearts
(p < 0.05).
LV parameters, LV internal diameter (LVID), and LV
average wall thickness (AWT) were recorded at baseline
(Figure 1). LVIDwas 1.49 ± 0.09mm and 1.44 ± 0.08mm
in WT (n = 6) and EphA2-R-M (n = 7) hearts, respectively
(p = 0.69). LV AWT in WT (n = 6) and EphA2-R-M (n = 7)
hearts was 1.83 ± 0.06 and 1.57 ± 0.05mm, respectively
(p < 0.01). No differences in MCSA were observed (data not
shown).
FIGURE 1 | Representative H&E Stains and Morphometry of Baseline
WT and EphA2-R-M Hearts. WT (A) and EphA2-R-M (B) hearts from
baseline mice were stained with H&E (20x). The LV cross-sectional area of
the EphA2-R-M hearts was 40% smaller than WT hearts (p < 0.05). At
baseline, LVID was 1.49 ± 0.09mm and 1.44 ± 0.08mm in B6 WT (n = 6)
and EphA2-R-M (n = 7) mice, respectively. AWT was 14% less in
EphA2-R-M (n = 7) hearts compared with WT (n = 6) hearts (∗p < 0.01) (C).
AWT, average wall thickness; LV, left ventricle; LVID, Left ventricular internal
diameter.
ROLE OF EphA2-R IN ACUTE INJURY
Infarct size
IS was calculated 4 days after infarction in WT (n = 12) and
EphA2-R-M (n = 9) hearts (Figure 2). IS was 37.54 ± 4.31%
and 49.46 ± 3.29% in WT and EphA2-R-M hearts, respectively
(p < 0.05). Area of necrosis was increased by 113% in EphA2-
R-M hearts compared with WT (p < 0.05). LVID was increased
by 59% and 53% in EphA2-R-M (n = 12) and WT (n = 10)
hearts (NS), respectively. No difference in LV AWT was observed
in EphA2-R-M (1.34 ± 0.05mm) hearts compared with WT
(1.31 ± 0.06mm). There were no differences in MCSA (data not
shown).
Ly6-G+ neutrophil density
Neutrophil infiltration was increased in baseline EphA2-R-M
mice and this difference increased by 46% after MI (Figure 3).
Ly6-G+ staining of neutrophil density in WT (n = 6) hearts
was 0.21 ± 0.04 cells/0.1mm2 and 3.48 ± 0.29 cells/0.1mm2 in
EphA2-R-M (n = 3) hearts (p < 0.01). Ly6-G+ staining 4 days
post-MI in WT (n = 10) hearts was 46.96 ± 4.39 cells/0.1mm2
compared with 68.56 ± 8.59 cells/0.1mm2 in EphA2-R-M
(n = 9) hearts (p < 0.05).
CD45+ leukocyte density
Leukocyte density in control animals was no different between
WT and EphA2-R-M hearts (Figure 4). CD45+ staining of
leukocyte infiltration in WT (n = 3) mice was 7.63 ± 1.81
leukocyte/μm2 compared with 12.54 ± 2.41 leukocyte/μm2 in
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FIGURE 2 | Representative H&E Stains and Morphometry of WT and
EphA2-R-M Hearts 4 Days Post-MI. H&E Stain of WT (A) and EphA2-R-M
(B) hearts 4-days post-MI. Infarct Size (C) was increased by 31.7% in
EphA2-R-M hearts (∗p < 0.05) and Area of Necrosis (D) was increased by
113% compared with WT hearts (∗p < 0.05). LVID in EphA2-R-M hearts was
increased by 59% after infarction and increased by 53% in WT hearts (E).
G, Granulation Tissue; LV, left ventricle; LVID, Left ventricular internal
diameter; N, Necrosis; RV, Right Ventricle.
EphA2-RM (n = 10) hearts (p = 0.13). Leukocyte infiltration
was increased by 84% in EphA2-R-M hearts after MI compared
with WT hearts. CD45+ staining 4 days post-MI in WT (n = 7)
and EphA2-R-M (n = 8) hearts was 55.97 ± 5.55 leukocyte/μm2
and 102.76 ± 5.94 leukocyte/μm2, respectively (p < 0.001).
Western blotting
A 2.7-fold increase in NF-κB expression was observed in WT
(n = 3; p < 0.01) hearts 4 days post-MI compared with no
change in EphA2-R-M (n = 3) hearts (Figure 5A). Both pro-
and active-MMP-2 were increased 6- and 3-fold in WT mice 4
days post-MI, respectively (p < 0.05). No changes were observed
in MMP-2 expression in EphA2-R-M hearts 4 days post-MI
(Figure 5B). No differences in baseline expression of Akt or p-Akt
were observed between EphA2-R-M and WT mice. EphA2-R-M
hearts (n = 3) had 66.7% less expression of total Akt protein and
59% less p-Akt protein than WT (n = 3) hearts 4 days post-MI
(Figure 5C).
qRT-PCR
EphrinA1 and EphA-R gene expression was quantified using qRT-
PCRmRNA levels for baselineWTmice (n = 3) and EphA2-R-M
mice (n = 3) (Figure 6C). Although ephrinA1 expression was not
different between WT and EphA2-R-M mice at baseline, EphA6
FIGURE 3 | Neutrophil Infiltration in WT and EphA2-R-M Hearts at
Baseline and 4 Days Post-MI. Ly6-G+ neutrophil infiltration 4 days Post-MI
at 40x magnification in WT (A) and EphA2-R-M (B) hearts. Neutrophil
infiltration was increased by 46% in EphA2-R-M hearts (C; ∗p < 0.05).
FIGURE 4 | CD45+ Leukocyte Density in WT and EphA2-R-M Hearts at
Baseline and 4 Days Post-MI. Leukocyte density staining 4 days post-MI
at 40x magnification in WT (A) and EphA2-R-M (B) hearts. Leukocyte
infiltration was increased by 84% in EphA2-R-M hearts after MI compared
with WT hearts (C; ∗p < 0.001).
gene expression was 2.5-fold greater in EphA-R-M (Figure 6B)
mice compared with WT (Figure 6A) mice (p < 0.05). Of note,
EphA3 gene expression was 2.06-fold greater in EphA2-R-Mmice
compared with WT; however, this difference was not statistically
significantly (p = 0.06).
EphrinA1 and EphA-R gene expression also was quantified
in WT (n = 3) and EphA2-R-M (n = 3) hearts 4 days post-
MI (Figure 6F). The expression of ephrinA1 was decreased
42% in EphA2-R-M hearts compared with WT mice (p <
0.01). EphA6-R expression was 9.8-fold greater in EphA2-R-M
(Figure 6E) mice compared with WT (Figure 6D) mice 4 days
post-MI (p = 0.01).
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FIGURE 5 | Western Blotting of NF-κB, MMP-2, and Akt in WT,
and EphA2-R-M Hearts. NF-κB expression (A) was elevated nearly
3-fold in WT hearts 4 days post-MI compared with baseline
(∗p < 0.01). A similar increase was not observed in EphA2-R-M
hearts compared with baseline. Both MMP-2 proenzyme and active
form were 6- and 3-fold higher in WT hearts post-MI (B)
respectively (∗p < 0.05). No change in MMP-2 expression was
observed in EphA2-R-M hearts. The expression of Akt and p-Akt
was significantly decreased in EphA2-R-M hearts post-MI and it
was unchanged in WT hearts (∗p < 0.05) (C).
EphA6-R immunohistochemistry
Increased expression of EphA6-R in EphA2-R-M mice was
noted in mice 4 days post-MI compared with WT mice
(Figure 6E). This was supported by the gene expression profile
of the EphA6-R observed in EphA2-R-M mice 4 days post-MI
(Figure 6F).
ROLE OF THE EphA2-R IN THE PROGRESSION OF ISCHEMIC
CARDIOMYOPATHY
Left-ventricular dimensions
Images ofWT and EphA2-R-M hearts 4 weeks post-MI are shown
in Figure 7. EphA2-R-M hearts had a 34% increase in LVID com-
pared with WT hearts. WT (n = 6) mice observed a LVID of
2.33 ± 0.21mm and EphA2-R-M (n = 5) mice had a LVID of
3.10 ± 0.26mm (p < 0.05). AWT in WT (n = 6) and EphA2-R-
M (n = 5) mice was 1.28± 0.22mm and 0.63± 0.24, respectively
(p < 0.05). No differences in MCSA were observed (data not
shown).
Fibrosis
Interstitial fibrosis was not different between WT and EphA2-R-
M mice at baseline and 4 weeks post-MI (Figure 8). Interstitial
fibrosis, presented as a percentage of the LV, inWT (n = 3) hearts
was 0.31 ± 0.22% compared with 0.10 ± 0.02% in EphA2-R-
M (n = 5) hearts (p = 0.43). There was a 26% increase (p <
0.01) in interstitial fibrosis in EphA2-R-M hearts (2.34 ± 0.08%)
compared with WT (1.74 ± 0.18%).
Capillary density
Endocardial capillary density in baseline hearts was 31% less in
EphA2-R-M (n = 5) hearts compared with WT (n = 6) (WT:
170 ± 20 vessels per 400x high power field; EphA2-R -M: 117 ±
7 vessels per 400x high power field; p = 0.04) and epicardial cap-
illary density was decreased 24% in EphA2-R-M mice compared
withWT (WT: 134± 15 vessels per 400x high power field; EphA2-
R-M: 101 ± 12 vessels per 400x high power field; p < 0.05).
Endocardial capillary density 4 days post-MI was reduced by
63% in EphA2-R-M hearts (Figure 9A). WT mice (n = 4) and
EphA2-R-M (n = 6) endocardial capillary density was 31 ± 4
vessels per 400x high power field and 12 ± 1 vessels per 400x
high power field, respectively (p = 0.02). In the epicardium 4 days
post-MI, there were 27 ± 2 vessels per 400x high power field in
WT mice (n = 4) and 9 ± 7 vessels per 400x high power field in
EphA2-R-M mice (n = 6) (p < 0.01) (Figure 9A).
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FIGURE 6 | EphA6-R Staining and EphA-R Gene Expression Profiles in
WT and EphA2-R-M Hearts at Baseline and 4 Days Post-MI.
Representative immunohistochemical staining at 40x of EphA6-R in WT (A)
and EphA2-R-M (B) baseline hearts and 4 days post-MI (WT: D; EphA2-R-M:
E). EphrinA1 ligand and EphA-R gene expression in WT and EphA2-R-M
hearts was performed in hearts at baseline (C) and 4 days post-MI (F). In
baseline hearts, EphA6-R gene expression was 2.5-fold greater in
EphA2-R-M hearts (∗p < 0.05) (C). EphrinA1 ligand expression was
decreased 42% (∗p < 0.01) and EphA6-R expression was increased 9.8-fold
in EphA2-R-M hearts (∗p < 0.01) (F).
Four weeks post-MI, capillary density in the endocardium of
EphA2-R-M hearts was decreased by 53% compared with WT
hearts (Figure 9B). Endocardial capillary density 4 weeks post-
MI in WT mice (n = 5) and EphA2-R-M mice (n = 3) was
32 ± 2 vessels per 400x high power field and 15 ± 1 vessels
per 400x high power field, respectively (p < 0.01). In the epi-
cardium, capillary density in EphA2-R-M hearts was reduced by
47% compared withWT (Figure 9B). WTmice (n = 5) had 23 ±
1 vessels per 400x high power field and EphA2-R-Mmice (n = 3)
had a capillary density of 13 ± 1 vessels per 400x high power
field (p < 0.01).
FIGURE 7 | H&E Stain of WT and EphA2-R Hearts 4 Weeks Post-MI.
WT (A) and EphA2-R-M (B) hearts 4 weeks post-MI were stained with
H&E (20x). LVID increased by 35% (∗p < 0.05) in EphA2-R-M from 4 days
to 4 weeks post-MI (C). In WT hearts, LVID was relatively unchanged.
AWT decreased by 53% (∗p < 0.05) in EphA2-R-M at 4 weeks compared
to 4 days while AWT was increased by 78% (∗p < 0.05) in WT 4 weeks
post-MI (D). LVID, Left ventricular internal diameter; AWT, average wall
thickness.
FIGURE 8 | Interstitial Fibrosis in WT and EphA2-R-M Mice 4 Weeks
Post-MI. WT (A) and EphA2-R-M (B) images depicting interstitial fibrosis 4
weeks after infarction (400x). EphA2-R-M hearts had 26% (∗p < 0.01) more
fibrosis present 4 weeks post-MI compared with WT hearts (C).
Cardiac function
No differences in blood pressure or heart rate in conscious
mice between WT and EphA2-R-M mice was observed (data
not shown). Cardiac function in EphA2-R-M mice was signif-
icantly poorer than WT mice at baseline and 4 weeks post-MI
(Figure 10). Baseline ejection fraction in WT (n = 11) mice was
94.85 ± 0.85% compared with 78.99 ± 1.51% in EphA2-R-M
(n = 22) mice (p < 0.001). Ejection fraction 4 weeks post-MI in
WT (n = 5) and EphA2-R-M (n = 12) mice was 64.91 ± 3.70%
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FIGURE 9 | Capillary Density of WT and EphA2-R-M Hearts 4 Days and
4 Weeks Post-MI. Both endocardial and epicardial capillary density were
significantly reduced in EphA2-R-M hearts compared with WT 4 days (A)
and 4 weeks (B) post-MI (∗p < 0.05).
FIGURE 10 | WT and EphA2-R-M Cardiac Function at Baseline and 4
Weeks Post-MI. Baseline EphA2-R-M mice exhibited cardiac dysfunction
compared with baseline WT mice and ejection fraction and fractional
shortening were depressed in both strains at 4 weeks post-MI with more
significant dysfunction observed in EphA2-R-M mice at 4 weeks post-MI
(Ejection Fraction: ∗p < 0.01; Fractional Shortening: ∗p < 0.05).
and 52.78 ± 3.59%, respectively (p = 0.04). Baseline fractional
shortening in WT mice was 68.74 ± 6.6% compared with 49.72
± 11.04% in EphA2-R-M (p < 0.001). At 4 weeks post-MI, frac-
tional shortening was 35.40 ± 6.23% in WT mice and 26.89
± 7.69% in EphA2-R-M mice (p < 0.05). Chamber dimen-
sions obtained with echocardiographic imaging (data not shown)
follow the same trends as those obtained with morphometric
analyses.
DISCUSSION
This is the first report to examine the EphA2-R’s role in reg-
ulating the cellular events after permanent coronary occlusion
and its involvement in the progression of ischemic cardiomy-
opathy. Specifically, we have demonstrated that the EphA2-R
exacerbates the inflammatory response and influences early car-
diomyocyte injury that ultimately affects chronic ventricular
remodeling.
Currently, the EphA2-R’s involvement in regulating acute
ischemic injury in the heart is unknown. In a model of ischemic
brain injury, Thundyil et al. observed less inflammatory cell infil-
trate and reduced apoptosis in EphA2-R-Mmice (Thundyil et al.,
2013). In contrast, EphA2-R activation protects HL-1 cardiomy-
ocytes from apoptosis and ischemic injury in the kidney (Baldwin
et al., 2006; Jehle et al., 2012). These findings provide evidence
that the regulation of acute ischemia by the EphA2-R is a tissue-
and cell-specific phenomenon.
EphrinA reverse signaling has been implicated in regula-
tion of Akt phosphorylation and inhibition of apoptosis (Holen
et al., 2008). Additionally, our lab has shown that the upreg-
ulation and phosphorylation of Akt protein is associated with
improved cardiomyocyte survival in ephrinA1-Fc treated hearts
(Brantley-Sieders et al., 2005; Dries et al., 2011). In the current
study, we observed decreased expression of Akt and p-Akt in
EphA2-R-M hearts 4 days post-MI compared with WT, impli-
cating the EphA2-R’s role in modulating cardioprotective Akt
signaling.
Necrotic cardiomyocytes trigger an inflammatory response,
involving the transmigration of neutrophils and leukocytes which
clear debris and release cytokines to promote granulation tissue
formation (Frangogiannis et al., 2002; Virag and Murry, 2003;
Frangogiannis, 2008, 2012). Neutrophil and macrophage infil-
tration were significantly increased in EphA2-R-M mice 4 days
post-MI while NF-κB expression was decreased. This paradoxical
finding suggests that EphA2-R-M cardiomyocytes have lost their
ability to regulate inflammation after infarction. Additionally,
the increased residual necrosis and decreased MMP-2 synthe-
sis and activation in EphA2-R-M hearts potentially is explained
by defective inflammatory cell function resulting from deficient
NF-κB expression, leading to poorer remodeling and dysfunc-
tion. The EphA2-R is a known regulator of inflammation in
endothelial cells (Funk et al., 2012; Funk and Orr, 2013) and
infiltration of leukocytes occurs in lung tissue deficient of this
receptor (Okazaki et al., 2009). Therefore, our work provides evi-
dence that the EphA2-R modulates inflammation in the ischemic
myocardium and that defective regulation leads to an elevated
inflammatory response. Further studies are needed to examine
the cell-specific molecular consequences of NF-κB deficiency in
EphA2-R-M mice.
Macrophages persist in the infarcted area after MI and release
chemokines, such as MCP-1 and IL-1β, which recruit fibrob-
lasts to deposit collagen to form fibrotic scar tissue. This ulti-
mately leads to progressive ventricular dilation and dysfunction
(Nian et al., 2004; Frangogiannis and Entman, 2005). Increased
macrophage infiltration and subsequent collagen deposition were
observed in EphA2-R-M mice. The resultant enhanced ventric-
ular wall thinning explains the poorer functional capacity of
EphA2-R-M mice. Also, a 6-fold change in MMP-2 pro-enzyme
expression and a 3-fold increase in the active form were observed
in WT mice 4 days post-MI. However, in EphA2-R-M mice, no
significant changes in either form of MMP-2 were observed at
baseline or 4 days post-MI. The EphA2-R mediates the acute
inflammatory response post-MI and this ultimately influences
chronic ventricular remodeling leading to ischemic cardiomy-
opathy. Cell-specific expression of EphA2-R in the various cells
involved in matrix turnover will give further insight into this
mechanism.
The EphA2-R is an established angiogenic factor that con-
tributes to vascular development and post-natal angiogenesis.
In isolated human brain endothelial cells, inhibition of the
EphA2-R with siRNA has been shown to reduce angiogenesis
(Zhou et al., 2011). Overexpression of the EphA2-R is asso-
ciated with increased angiogenesis in ovarian cancer cells and
tumorigenesis is impaired in EphA2-R deficient mice (Brantley-
Sieders et al., 2005; Merritt et al., 2011). While angiogenesis in
oncogenic pathologies is undesirable, similar mechanisms exist
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as pro-angiogenic stimuli in ischemic tissue which may present
a clinical dilemma requiring careful pre-treatment evaluation.
The pro-angiogenic properties of the EphA2-R in the heart and
in response to ischemia have not been previously described.
The capillary density in the endocardium and epicardium was
significantly reduced in baseline EphA2-R-M mice and this dif-
ference persisted after infarction. This finding supports the role of
EphA2-R in vascular development and post-MI neo-angiogenesis
in the murine heart.
To our knowledge, the functional capacity of mice deficient of
the EphA2-R has not been reported. At baseline, ejection frac-
tion of EphA2-R-M mice was slightly but significantly reduced
compared with WT animals, suggesting a developmental role
of the EphA2-R in the functional capacity of the heart. The
EphA2-R has been implicated in spinal neuralation (Abdul-
Aziz et al., 2009). However, no literature exists on its role in
cardiac development or in cardiac physiology. Decreased cap-
illary density potentially explains the poorer function of the
EphA2-R-M mice. This would result in a limited ability of the
myocardium to respond to alterations in perfusion or oxygen
concentration. Although we have not performed functional anal-
yses of the vessels or determined whether this deficiency alters
perfusion, it is possible that the inadequate revascularization
we observed post-MI explains our findings in the EphA2-R-M
myocardium.
Our previous work has reported that the expression profiles
of the ephrinA1 ligand and the EphA-Rs (A1-4, 6, and 7) change
in the heart after MI and with treatment of exogenous ephrinA1-
Fc ligand (Dries et al., 2011). In our prior study, the EphA6-R
was downregulated and the EphA2-R was reciprocally upregu-
lated in response to MI and with ephrinA1-Fc treatment. The
current study supports the reciprocal expression profile of the
EphA2-R and the EphA6-R as EphA6-R expression was increased
in EphA2-R-M mice. Potentially, significant cross-talk between
these receptors exist to alter activation or inhibition of each
receptor such that EphA6 upregulation in the EphA2-R-M off-
sets the deleterious effects of the absence of EphA2-R. This is
supported by the fact that EphA and EphB receptors have been
shown to form heterotypic clusters upon ligand binding and
activation or inhibition of the signaling cascades depends on
these receptors’ specific interactions (Janes et al., 2011). The
EphA2-R most likely mediates cardioprotection and interacts
with the EphA6-R to decrease potential negative sequelae medi-
ated through this receptor. Further studies to characterize the
cell-specific expression profiles of the EphA2-R and EphA6-R
are needed to elucidate their interaction and role in post-MI
myocardium.
Expression of the protective ephrinA1 ligand was significantly
decreased in EphA2-R-M mice after MI. This is consistent with
our previous work (Dries et al., 2011). The reduction in the eph-
rinA1 ligand gene expression in our current study supports our
previous finding that the cardioprotective benefits of endogenous
ephrinA1 are lost after MI and worsened in EphA2-R-M mice.
Since this study does not explore the potential of ephrinA1 treat-
ment to reduce injury during MI, further studies are warranted
to determine if the cardioprotective benefits of this ligand can be
reproduced in mice that lack the EphA2-R.
In conclusion, this study has demonstrated the complex
role of the EphA2-R in the heart after MI. The EphA2-R is
a critical mediator of inflammation and early injury during
acute MI which influences the progression of ischemic car-
diomyopathy. EphrinA1-EphA signaling represents an exciting
new area of exploration in the heart and further studies are
needed to determine their role and therapeutic potential to blunt
injury in MI.
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